Merck & Co., Inc. (NYSE:MRK) Stock Jumps 3.6% – Still a Buy?

Shares of Merck & Co., Inc. (NYSE:MRK) traded up 3.6% on Wednesday. The stock traded as high as $146.67 and last traded at $147.1410. Approximately 2,234,501 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 10,586,647 shares. The stock had previously closed at $141.98.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda and pipeline catalysts support earnings outlook: Keytruda sales growth, expanded indications and launches of earlier-stage products could help Merck deliver stronger third-quarter revenue ahead of its earnings report in the next few weeks. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Upcoming ESMO data boosts pipeline optimism: Merck will present first-time Phase 3 results from three pivotal oncology trials, along with more than 90 additional abstracts across over 20 tumor types. Positive results could strengthen confidence in growth beyond Keytruda and help address its eventual loss of exclusivity. Merck Showcases First-Time Pivotal Phase 3 Results
• Positive Sentiment: Analyst support: Leerink Partners initiated or reiterated a Buy rating, adding to the positive sentiment around Merck’s valuation and pharmaceutical pipeline. Merck Gets a Buy from Leerink Partners
• Neutral Sentiment: Board appointment: Paul J. Diaz was elected to Merck’s board, adding healthcare and management experience but offering little immediate earnings impact. Paul J. Diaz Elected to Merck Board
• Negative Sentiment: Pipeline and competitive risks weigh on the story: Jefferies cut its peak-sales forecast for experimental eye drug remigromig by 60% after efficacy and safety concerns. Keytruda also faces biosimilar competition in 2028–2029, while Erste Group modestly reduced its 2026 and 2027 EPS estimates. Merck’s elevated valuation and reported negative operating margin could amplify downside if results disappoint. Jefferies Cuts Merck’s Remigromig Sales Forecast

Analyst Ratings Changes

A number of research firms have issued reports on MRK. Guggenheim increased their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. The Goldman Sachs Group upped their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. Citigroup upped their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Finally, HSBC lifted their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Trading Up 3.6%

The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market cap of $362.91 billion, a PE ratio of 118.45, a price-to-earnings-growth ratio of 6.72 and a beta of 0.21. The firm has a 50-day moving average price of $144.52 and a 200-day moving average price of $128.73.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insider Activity

In other news, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. The trade was a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP David Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Round Rock Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares in the last quarter. Cascade Financial Partners LLC boosted its position in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after purchasing an additional 80 shares during the last quarter. Somerset Trust Co grew its stake in Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after purchasing an additional 81 shares in the last quarter. Stonebridge Financial Group LLC grew its stake in Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after purchasing an additional 81 shares in the last quarter. Finally, Stronghold Wealth Management L.L.C. increased its position in shares of Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after purchasing an additional 82 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.